secwatch.observer — SEC 8-K summary
======================================

Issuer:     Citius Pharmaceuticals, Inc. (CTXR)
CIK:        0001506251
Form:       8-K
Filed at:   2025-02-14T23:59:59+00:00
Accession:  0001213900-25-014359
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 8.01, 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Citius Pharma Q1 2025 net loss $10.3M; prepares LYMPHIR launch H1 2025
----------------------------------------------------------------------

- Net loss of $10.3M ($1.30 per share) vs. $9.2M ($1.45) in Q1 2024; cash $1.1M as of Dec 31, 2024.
- G&A expenses rose to $5.4M on pre-launch LYMPHIR activities; R&D fell to $2.1M as trials completed.
- LYMPHIR received permanent J-code (J9161) effective April 1, 2025; launch expected in first half 2025.
- Citius Oncology engaged Jefferies to evaluate strategic alternatives; raised $6.5M in equity placements.
- Nasdaq compliance regained after 1-for-25 reverse stock split in November 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1506251/000121390025014359/0001213900-25-014359-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1506251/000121390025014359/ea0231245-8k_citius.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-014359

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer